Brean Murray Carret & Co. Adjusting Estimates & PT InterMune Inc. (ITMN); Timelines Push Things Back

April 10, 2012 8:56 AM EDT Send to a Friend
Get Alerts ITMN Hot Sheet
Price: $9.58 -3.82%

Rating Summary:
    11 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 18 | New: 13
Trade ITMN Now!
Brean Murray Carret & Co. maintains a 'Buy' on InterMune Inc. (NASDAQ: ITMN) price target lowered from $42 to $37.

Last night, Brian Skorney, said, "The French Commission de Transparence (CT) indication that Esbriet does provide a benefit, which should offer the company good-pricing advantage in France. We continue to see upside...However, guidance that timelines to commercial launch in Europe and Phase 3 data for U.S. approval are delayed may be a good source of frustration given how recently mgmt had provided and reiterated timelines."

Skorney lowers FY12 loss from (2.35) to (2.47) and FY13 from (0.42) to (1.13)

For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.

Shares of InterMune Inc. closed at $12.90 yesterday, with a 52 week range of $10.67-$51.71.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, FDA

Related Entities

Brean Murray Carret & Co.

Add Your Comment